Investigational Drug Information for Rimiducid
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
What is the drug development status for Rimiducid?
Rimiducid is an investigational drug.
There have been 21 clinical trials for Rimiducid.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 27th 2018.
The most common disease conditions in clinical trials are Myelodysplastic Syndromes, Preleukemia, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are Bellicum Pharmaceuticals, Poseida Therapeutics, Inc., and National Cancer Institute (NCI).
There are fourteen US patents protecting this investigational drug and two hundred and forty-four international patents.
Summary for Rimiducid
| US Patents | 14 |
| International Patents | 244 |
| US Patent Applications | 169 |
| WIPO Patent Applications | 150 |
| Japanese Patent Applications | 67 |
| Clinical Trial Progress | Phase 1 (2018-12-27) |
| Vendors | 33 |
Recent Clinical Trials for Rimiducid
| Title | Sponsor | Phase |
|---|---|---|
| P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors | Poseida Therapeutics, Inc. | Phase 1 |
| P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma | Poseida Therapeutics, Inc. | Phase 1 |
| Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial | National Cancer Institute (NCI) | Phase 1 |
Clinical Trial Summary for Rimiducid
Top disease conditions for Rimiducid
Top clinical trial sponsors for Rimiducid
US Patents for Rimiducid
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Rimiducid | ⤷ Sign Up | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | ⤷ Sign Up |
| Rimiducid | ⤷ Sign Up | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | ⤷ Sign Up |
| Rimiducid | ⤷ Sign Up | Treatment of cancer using a CLL-1 chimeric antigen receptor | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | ⤷ Sign Up |
| Rimiducid | ⤷ Sign Up | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | ⤷ Sign Up |
| Rimiducid | ⤷ Sign Up | Compositions and methods for treatment of cancer | Aleta Biotherapeutics Inc. (Natick, MA) | ⤷ Sign Up |
| Rimiducid | ⤷ Sign Up | Treatment of cancer using a CD123 chimeric antigen receptor | The Trustees of the University of Pennsylvania (Philadelphia, PA) Novartis AG (Basel, CH) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Rimiducid
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Rimiducid | Argentina | AR102035 | 2034-07-21 | ⤷ Sign Up |
| Rimiducid | Australia | AU2015292744 | 2034-07-21 | ⤷ Sign Up |
| Rimiducid | Australia | AU2020202726 | 2034-07-21 | ⤷ Sign Up |
| Rimiducid | Brazil | BR112017001183 | 2034-07-21 | ⤷ Sign Up |
| Rimiducid | Canada | CA2955386 | 2034-07-21 | ⤷ Sign Up |
| Rimiducid | China | CN106687483 | 2034-07-21 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
